[SCHEDULE 13G/A] Sarepta Therapeutics,, Inc. SEC Filing
Sarepta Therapeutics received a Schedule 13G/A from Capital International Investors disclosing a passive, beneficial holding of 524,146 common shares, equal to 0.5% of the 98,277,032 shares reported outstanding. The filing identifies Capital International Investors as a division of Capital Research and Management Company and related investment management entities and states that those entities are collectively deemed the beneficial owner of the position.
The report shows detailed control metrics: sole voting power for 523,807 shares, sole dispositive power for 524,146 shares and no shared voting or dispositive power. The filing also certifies the shares are held in the ordinary course of business and not to change or influence control of the issuer.
Sarepta Therapeutics ha ricevuto un Schedule 13G/A da Capital International Investors che dichiara una partecipazione beneficiaria passiva di 524,146 azioni ordinarie, pari a 0.5% delle 98,277,032 azioni segnalate in circolazione. La comunicazione identifica Capital International Investors come divisione di Capital Research and Management Company e relative entit脿 di gestione degli investimenti, e specifica che tali entit脿 sono collettivamente considerate i beneficiari della posizione.
Il rapporto riporta metriche di controllo dettagliate: potere di voto esclusivo su 523,807 azioni, potere di disposizione esclusivo su 524,146 azioni e nessun potere di voto o di disposizione condiviso. La comunicazione certifica inoltre che le azioni sono detenute nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo dell'emittente.
Sarepta Therapeutics recibi贸 un Schedule 13G/A de Capital International Investors que revela una tenencia beneficiaria pasiva de 524,146 acciones ordinarias, equivalente a 0.5% de las 98,277,032 acciones reportadas en circulaci贸n. la presentaci贸n identifica a Capital International Investors como una divisi贸n de Capital Research and Management Company y entidades relacionadas de gesti贸n de inversiones, y afirma que dichas entidades son colectivamente consideradas beneficiarias de la posici贸n.
El informe muestra m茅tricas de control detalladas: poder de voto exclusivo sobre 523,807 acciones, poder dispositvo exclusivo sobre 524,146 acciones y 苍颈苍驳煤苍 poder de voto o dispositvo compartido. La presentaci贸n tambi茅n certifica que las acciones se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Sarepta Therapeutics電� Capital International Investors搿滊秬韯� Schedule 13G/A毳� 鞝戩垬頄堨溂氅�, 靾橂彊鞝�(牍勴櫆霃欖爜)鞙茧 524,146 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 瓿奠嫓頄堨姷雼堧嫟. 鞚措姅 氤搓碃霅� 鞙犿喌 欤检嫕 98,277,032欤检潣 0.5%鞐� 頃措嫻頃╇媹雼�. 靹滊電� Capital International Investors毳� Capital Research and Management Company鞚� 頃� 攵�靹滌澊鞛� 甏�霠� 韴瀽鞖挫毄 旮瓣磤鞙茧 攴滌爼頃橁碃, 鞚措摛 旮瓣磤鞚� 歆戨嫧鞝侅溂搿� 頃措嫻 歆�攵勳潣 鞁れ鞝� 靻岇湢鞛�(beneficial owner)搿� 臧勳＜霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
氤搓碃靹滌棎電� 靸侅劯頃� 韱奠牅 歆�響滉皜 雮橃檧 鞛堨姷雼堧嫟: 雼弲 鞚橁舶甓�鞚赌 523,807欤检棎 雽�頃�, 雼弲 觳橂秳甓�鞚赌 524,146欤检棎 雽�頃� 氤挫湢頃橂┌ 瓿惦彊 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澏� 鞐嗠嫟瓿� 氤搓碃頃╇媹雼�. 霕愴暅 鞚� 欤检嫕霌れ澏� 鞓侅梾靸侅潣 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Sarepta Therapeutics a re莽u un Schedule 13G/A de Capital International Investors r茅v茅lant une d茅tention b茅n茅ficiaire passive de 524,146 actions ordinaires, soit 0.5% des 98,277,032 actions signal茅es en circulation. Le dossier identifie Capital International Investors comme une division de Capital Research and Management Company et des entit茅s de gestion d'investissements associ茅es, et indique que ces entit茅s sont collectivement consid茅r茅es comme les propri茅taires effectifs de la position.
Le rapport pr茅sente des indicateurs de contr么le d茅taill茅s : pouvoir de vote exclusif sur 523,807 actions, pouvoir discr茅tionnaire exclusif sur 524,146 actions et aucun pouvoir de vote ou discr茅tionnaire partag茅. Le dossier certifie 茅galement que les actions sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Sarepta Therapeutics erhielt ein Schedule 13G/A von Capital International Investors, das eine passive wirtschaftliche Beteiligung von 524,146 Stammaktien offenlegt, was 0.5% der gemeldeten 98,277,032 ausstehenden Aktien entspricht. Die Einreichung bezeichnet Capital International Investors als eine Abteilung der Capital Research and Management Company sowie verbundene Investment-Management-Einheiten und erkl盲rt, dass diese Einheiten gemeinsam als wirtschaftlicher Eigent眉mer der Position angesehen werden.
Der Bericht f眉hrt detaillierte Kontrollkennzahlen auf: alleiniges Stimmrecht 蹿眉谤 523,807 Aktien, alleiniges Verf眉gungsrecht 蹿眉谤 524,146 Aktien und keine geteilten Stimm- oder Verf眉gungsrechte. Die Einreichung best盲tigt au脽erdem, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf gehalten werden und nicht dazu dienen, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
- Provides clear, specific disclosure of beneficial ownership: 524,146 shares representing 0.5% of the reported outstanding common stock.
- Details control metrics with sole voting power for 523,807 shares and sole dispositive power for 524,146 shares, improving transparency.
- None.
Insights
TL;DR: A routine passive disclosure 鈥� CII holds 524,146 SRPT shares (0.5%), a non鈥慶ontrolling stake with clear voting/dispositive breakdowns.
The position represents a small stake relative to the reported float and falls well below 5%, so it is unlikely to affect company control or market dynamics on its own. The filing provides useful granularity: sole voting power over 523,807 shares and sole dispositive power over 524,146 shares. For investors, the filing mainly confirms ownership and governance posture rather than signaling strategic change.
TL;DR: Governance disclosure is complete and consistent with a passive investor profile; no group affiliations or control intent are indicated.
The Schedule 13G/A classifies the filer as an investment adviser division and explicitly states the securities are held in the ordinary course of business, which aligns with passive investor treatment. The absence of shared voting/dispositive power and the certification against influencing control reduce regulatory and governance concerns. The filing does not identify any subgroup arrangements or intentions to form a group to impact issuer control.
Sarepta Therapeutics ha ricevuto un Schedule 13G/A da Capital International Investors che dichiara una partecipazione beneficiaria passiva di 524,146 azioni ordinarie, pari a 0.5% delle 98,277,032 azioni segnalate in circolazione. La comunicazione identifica Capital International Investors come divisione di Capital Research and Management Company e relative entit脿 di gestione degli investimenti, e specifica che tali entit脿 sono collettivamente considerate i beneficiari della posizione.
Il rapporto riporta metriche di controllo dettagliate: potere di voto esclusivo su 523,807 azioni, potere di disposizione esclusivo su 524,146 azioni e nessun potere di voto o di disposizione condiviso. La comunicazione certifica inoltre che le azioni sono detenute nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo dell'emittente.
Sarepta Therapeutics recibi贸 un Schedule 13G/A de Capital International Investors que revela una tenencia beneficiaria pasiva de 524,146 acciones ordinarias, equivalente a 0.5% de las 98,277,032 acciones reportadas en circulaci贸n. la presentaci贸n identifica a Capital International Investors como una divisi贸n de Capital Research and Management Company y entidades relacionadas de gesti贸n de inversiones, y afirma que dichas entidades son colectivamente consideradas beneficiarias de la posici贸n.
El informe muestra m茅tricas de control detalladas: poder de voto exclusivo sobre 523,807 acciones, poder dispositvo exclusivo sobre 524,146 acciones y 苍颈苍驳煤苍 poder de voto o dispositvo compartido. La presentaci贸n tambi茅n certifica que las acciones se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Sarepta Therapeutics電� Capital International Investors搿滊秬韯� Schedule 13G/A毳� 鞝戩垬頄堨溂氅�, 靾橂彊鞝�(牍勴櫆霃欖爜)鞙茧 524,146 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 瓿奠嫓頄堨姷雼堧嫟. 鞚措姅 氤搓碃霅� 鞙犿喌 欤检嫕 98,277,032欤检潣 0.5%鞐� 頃措嫻頃╇媹雼�. 靹滊電� Capital International Investors毳� Capital Research and Management Company鞚� 頃� 攵�靹滌澊鞛� 甏�霠� 韴瀽鞖挫毄 旮瓣磤鞙茧 攴滌爼頃橁碃, 鞚措摛 旮瓣磤鞚� 歆戨嫧鞝侅溂搿� 頃措嫻 歆�攵勳潣 鞁れ鞝� 靻岇湢鞛�(beneficial owner)搿� 臧勳＜霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
氤搓碃靹滌棎電� 靸侅劯頃� 韱奠牅 歆�響滉皜 雮橃檧 鞛堨姷雼堧嫟: 雼弲 鞚橁舶甓�鞚赌 523,807欤检棎 雽�頃�, 雼弲 觳橂秳甓�鞚赌 524,146欤检棎 雽�頃� 氤挫湢頃橂┌ 瓿惦彊 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澏� 鞐嗠嫟瓿� 氤搓碃頃╇媹雼�. 霕愴暅 鞚� 欤检嫕霌れ澏� 鞓侅梾靸侅潣 韱奠儊鞝侅澑 氩旍渼 雮挫棎靹� 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Sarepta Therapeutics a re莽u un Schedule 13G/A de Capital International Investors r茅v茅lant une d茅tention b茅n茅ficiaire passive de 524,146 actions ordinaires, soit 0.5% des 98,277,032 actions signal茅es en circulation. Le dossier identifie Capital International Investors comme une division de Capital Research and Management Company et des entit茅s de gestion d'investissements associ茅es, et indique que ces entit茅s sont collectivement consid茅r茅es comme les propri茅taires effectifs de la position.
Le rapport pr茅sente des indicateurs de contr么le d茅taill茅s : pouvoir de vote exclusif sur 523,807 actions, pouvoir discr茅tionnaire exclusif sur 524,146 actions et aucun pouvoir de vote ou discr茅tionnaire partag茅. Le dossier certifie 茅galement que les actions sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Sarepta Therapeutics erhielt ein Schedule 13G/A von Capital International Investors, das eine passive wirtschaftliche Beteiligung von 524,146 Stammaktien offenlegt, was 0.5% der gemeldeten 98,277,032 ausstehenden Aktien entspricht. Die Einreichung bezeichnet Capital International Investors als eine Abteilung der Capital Research and Management Company sowie verbundene Investment-Management-Einheiten und erkl盲rt, dass diese Einheiten gemeinsam als wirtschaftlicher Eigent眉mer der Position angesehen werden.
Der Bericht f眉hrt detaillierte Kontrollkennzahlen auf: alleiniges Stimmrecht 蹿眉谤 523,807 Aktien, alleiniges Verf眉gungsrecht 蹿眉谤 524,146 Aktien und keine geteilten Stimm- oder Verf眉gungsrechte. Die Einreichung best盲tigt au脽erdem, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf gehalten werden und nicht dazu dienen, die Kontrolle 眉ber den Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Sarepta (SRPT) shares does Capital International Investors report owning?
What percentage of SRPT does the 524,146 share position represent?
Does Capital International Investors have voting power over these SRPT shares?
Does the filer have the power to dispose of the reported SRPT shares?
Is this ownership reported as being held to influence control of Sarepta?
